secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARROW, INC. (HROW)
CIK:        0001360214
Form:       8-K
Filed at:   2024-08-07T23:59:59+00:00
Accession:  0001493152-24-030563
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harrow Q2 2024 record revenue $48.9M (+46% YoY); adj EBITDA $8.8M; guides FY rev >$180M
--------------------------------------------------------------------------------

- Record Q2 revenue $48.9M, up 46% YoY and 42% sequentially; GAAP net loss $(6.5)M.
- Adjusted EBITDA $8.8M; core gross margin 79% (up from 78%).
- IHEEZO unit demand up 98% QoQ; VEVYE prescriptions up 212% QoQ; new IHEEZO supply agreements.
- FY2024 revenue guidance >$180M (excluding TRIESENCE); expects back-half outperformance.
- TRIESENCE PPQ Batch 2 passes initial tests; third batch scheduled; potential 2024 relaunch.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1360214/000149315224030563/0001493152-24-030563-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1360214/000149315224030563/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-030563

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer